PRLD
PRELUDE THERAPEUTICS INCData as of 2026 Q2 (06-30) · 13F snapshot
Summary
PRELUDE THERAPEUTICS INC (PRLD) is held as common stock by 4 tracked hedge-fund managers, with a combined reported value of ~$60.08M; the largest are Baker Bros. Advisors, Izzy Englander, Renaissance Technologies. 1 tracked manager also disclosed PUT or CALL positions, reported separately below. This quarter: 2 added, 1 trimmed, 1 closed. Data as of 2026 Q2, from public SEC 13F filings, delayed up to ~45 days.
Attention · MediumThis quarter · Mixed
Common-stock holders41 also report options
Congress trades0
Price$3.91vs quarter-end-26.64%
Sectors0
This quarter's moves
Top holderBaker Bros. AdvisorsNew0
Added2
Trimmed / sold2
Common-stock positions
PUT and CALL disclosures are excluded from these holder counts and values.
Value $53.96M0.3% of portfolio10,123,8242026 Q2
| Investor | Value | % of portfolio | Action |
|---|---|---|---|
| Baker Bros. Advisors | $53.96M | 0.3% | Hold |
PUT / CALL disclosures
Reported separately: 13F option values are not common-stock ownership and do not reveal the full strategy or economic exposure.
Value $166.8K— of portfolio31,3002026 Q2
Value $85.8K— of portfolio16,1002026 Q2
| Investor | Value | % of portfolio | Action |
|---|---|---|---|
| Ken GriffinPUT | $166.8K | — | — |
| Ken GriffinCALL | $85.8K | — | — |
Public SEC 13F filings may appear up to 45 days after quarter-end; STOCK Act / OGE trade filings are generally due within 45 days but may be late. Partial data only — research, not investment advice.